Burrill & Company
93
19M
58
3.10
10
0.38
26
- Stages of investment
- Areas of investment
Summary
In 1994 was created Burrill & Company, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the San Francisco.
Comparing to the other companies, this Burrill & Company performs on 3 percentage points less the average number of lead investments. The top activity for fund was in 2004. The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies. The fund is generally included in 2-6 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2014. When the investment is from Burrill & Company the average startup value is 50-100 millions dollars.
This organization was formed by G. Steven Burrill. We also calculated 5 valuable employees in our database.
The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are Medical, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Catalyst Biosciences, diaDexus, Light Sciences Oncology. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Burrill & Company, startups are often financed by Khosla Ventures, DSM Venturing, Prolog Ventures. The meaningful sponsors for the fund in investment in the same round are Prolog Ventures, Great Spirit Ventures, Novo Holdings. In the next rounds fund is usually obtained by Novo Holdings, Morgenthaler Ventures, Prolog Ventures.
Investments analytics
Analytics
- Total investments
- 93
- Lead investments
- 10
- Exits
- 26
- Rounds per year
- 3.10
- Follow on index
- 0.38
- Investments by industry
- Biotechnology (78)
- Health Care (54)
- Medical (40)
- Pharmaceutical (30)
- Medical Device (16) Show 42 more
- Investments by region
-
- United States (88)
- United Arab Emirates (2)
- China (1)
- India (1)
- Peak activity year
- 2007
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 20
- Avg. valuation at time of investment
- 20M
- Group Appearance index
- 0.99
- Avg. company exit year
- 12
- Avg. multiplicator
- 0.84
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Alexza Pharmaceuticals | 25 Sep 2002 | Biotechnology, Health Care, Pharmaceutical | Early Stage Venture | 45M | United States, California, Mountain View |
| Arete Therapeutics | 19 Nov 2008 | Biotechnology, Health Care, Therapeutics | Early Stage Venture | 16M | United States, California, Hayward |
| Botin | 13 Apr 2022 | Asset Management, Internet, FinTech, Cryptocurrency, Wealth Management, Trading Platform, Stock Exchanges | Seed | England, London, United Kingdom |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.